학술논문
Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Document Type
Abstract
Author
Minson, Adrian; Hamad, Nada; Cheah, Chan Y.; Tam, Constantine S.; Blombery, Piers; Westerman, David A; Lade, Stephen ; Ritchie, David; Koldej, Rachel M ; Anderson, Mary Ann; Khot, Amit; Seymour, John F.; Robertson, Molly ; Caldwell, Imogen R; Ryland, Georgina L; Xie, Jing ; Morgan, Huw ; Dickinson, Michael
Source
In Blood 15 November 2022 140 Supplement 1:181-183
Subject
Language
ISSN
0006-4971